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Figure S1. Serum albumin trend after obinutuzumab.
Figure S2. Serum creatinine trend after obinutuzumab.
Table S1. Serum PLA2R antibody titer (RU/ml).
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F
ocal segmental glomerulosclerosis (FSGS) is one of
the most common causes of nephrotic syndrome in
adults, and the incidence of this diagnosis is
increasing.1–4 This histological diagnosis can result
from many conditions such as reflux nephropathy,
significant obesity, or genetic mutations affecting
structural elements of the glomerular filtration barrier.
The idiopathic form of this disease is due to a circu-
lating factor(s) that disrupt the glomerular filtration
barrier, resulting in widespread podocyte foot process
effacement (FPE) and proteinuria.5–7 Reported recur-
rence rates following the first kidney transplantation
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vary between 10% and 86%.8,9,S1 Following a repeat
transplantation, after an initial recurrence, the recur-
rence rate is approximately 90%.S1,S2 Recurrence post-
transplantation can result in significantly premature
graft loss.9,S2 The circulating factor(s) responsible for
idiopathic FSGS remain elusive.
Many investigators have proposed various clinical
and or histological markers, or a combination thereof,
to identify primary idiopathic FSGS.9,S1,S3–S5 None of
these have been able to predict recurrence following
kidney transplantation with accuracy greater than
86%. Currently, the diagnosis of recurrent primary
FSGS is made clinically, that is, development of pro-
teinuria early after transplantation.5,S1,S2 However, in a
number of patients, proteinuria develops later. The
true specificity of disease recurrence following trans-
plantation has not been examined.
We present 3 transplant recipients who developed
early post-transplantation FSGS following trans-
plantation (1 patient for the third time) who were
found to have etiologies other than idiopathic FSGS.
Being aware of these etiologies may prevent unnec-
essary therapy and also allow for better cohort defini-
tion, enabling identification of the elusive circulating
factor(s).
CASE 1
A 23-year-old African American man was found to
have hypertension, nephrotic range proteinuria, and
advanced renal failure. His kidneys were small and
atrophic bilaterally, precluding native kidney biopsy.
There was no history of nephrotoxic agents or family
history of kidney disease.
After 5 years on dialysis, he received a deceased
donor kidney transplant from an 18-year-old African
American donor. Implantation biopsy was without
any abnormality. Immunosuppression was induced
with alemtuzumab and maintained with dual therapy
consisting of tacrolimus and mycophenolate mofetil.
Because of concerns that he had primary FSGS, he
was placed on a heightened post-transplantation
monitoring regimen for albuminuria. The initial
post-transplantation course was uneventful, with a
normal protocol allograft biopsy at 4 months post-
transplantation and normal urine albumin excretion.
At 6 months post-transplantation, increasing albumin
excretion peaking at 3.4 g/g creatinine with stable
serum creatinine was noted (Figure 1). Allograft bi-
opsy showed segmental sclerosis in 2 of 15 glomeruli,
both of which had associated overlying podocyte
reaction and protein resorption granules, with patchy
mild mononuclear cell infiltrates involving less than
10% of the cortex with associated focal mild tubu-
litis. This was initially interpreted as clinically
recurrent FSGS with borderline changes for rejection
(Figure 2). Electron microscopy, however, showed
largely intact podocyte foot processes.
Treatment for the borderline rejection consisted of 5
consecutive days of parenteral methylprednisolone
with decreasing dosage, followed by a rapid oral
prednisone taper to 5 mg over 7 days. Given the lack of
podocyte FPE, no specific therapy for recurrent FSGS
was undertaken. Losartan 25 mg daily was substituted
for amlodipine 5 mg daily for blood pressure control.
A postrejection therapy follow-up biopsy sample
was obtained 4 weeks later and was normal.
Figure 1. Trends of serum creatinine, random albumin/creatinine ratio, 24-hour albumin excretion, and serum albumin from case 1. Steroid
therapy for borderline acute cellular rejection.
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Albuminuria decreased gradually over the following 4
months to <1 g/g creatinine, then to <0.5 g/g creati-
nine over the subsequent 2 months and has remained in
the range of 0.3 to 0.4 g/g creatinine over 2 years of
follow-up (Figure 1). Blood pressure and renal function
were stable throughout.
Given the unusual presentation, a thorough workup
for secondary causes of FSGS was undertaken. This
included apolipoprotein L 1 (APOL-1) testing of the
recipient and donor. The recipient was homozygous for
the average risk alleles, and the donor was homozygous
for the high-risk allele G1.
Interestingly, we were contacted by the center that
transplanted themate kidney of this recipient (see Case 2).
CASE 2
A 70-year-old Caucasian woman who developed end-
stage renal disease (ESRD) attributed to hypertensive
diabetic nephrosclerosis received a deceased donor
kidney transplant after 2.5 years of dialysis. Her
calculated panel reactive antibodies (cPRA) were 100%.
Prior to transplantation, she underwent desensitization
using plasma exchange (PLEX) and i.v. Ig. B-cell flow
crossmatch was weakly positive at the time of trans-
plantation. Induction was with antithymocyte glob-
ulin, and the patient was maintained on triple
immunosuppressive therapy consisting of corticoste-
roids, mycophenolate mofetil, and tacrolimus. Post-
transplantation she received rituximab and i.v. Ig
and required a blood transfusion. One week
post-transplantation there was an increase in donor-
specific antihuman leukocyte antigen (HLA)
antibodies (DSA). PLEX, i.v. Ig, and bortezomib were
administered, followed by a decrease in DSA levels.
Creatinine remained at baseline of 0.9 to 1.1 mg/dl. One
year post-transplantation proteinuria was noted at 4.3
g/g creatinine. Previous levels were <0.35 g/g creati-
nine, with the most proximate level being 40 weeks
before the detection of the nephrotic range proteinuria.
Renal allograft biopsy showed de novo collapsing glo-
merulopathy with extensive FPE. Testing for HIV,
Epstein-Barr virus, and Parvo virus was negative by
polymerase chain reaction. The patient was started on
an angiotensin receptor blocker. Her proteinuria
increased to 10 g/g creatinine, at which point she un-
derwent 5 sessions of PLEX and received additional
rituximab and i.v. Ig. There was a transient decrease in
proteinuria to 4.9 with stable graft function. Two
months, later proteinuria increased to 11 g/g creatinine.
Four months afterward, graft function began to dete-
riorate, with an increase in the baseline creatinine to
1.5 to 1.9 mg/dl, and 8 months later it was 4 mg/dl. A
second allograft biopsy sample showed advanced focal
and segmental sclerosis with no evidence of rejection
but some findings suggestive of allograft pyelonephri-
tis. An Escherichia coli urinary tract infection at that
time was treated, with no improvement in renal
Figure 2. Pathology of the 7-month post-transplantation kidney allograft biopsy from case 1: (a) light microscopy (original magnification 40,
periodic acid–Schiff) and (b) light microscopy (original magnification 40, Jones), both showing segmental sclerosis in glomeruli with overlying
podocyte reaction; and (c) electron microscopy photomicrograph demonstrating intact podocyte foot processes.
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function. Creatinine remained at 4.1 mg/dl and pro-
teinuria consistently >20 g/g creatinine. The patient
returned to maintenance hemodialysis 30 months post-
transplantation.
CASE 3
A 40-year-old Caucasian man with ESRD from biopsy-
proven FSGS at age 16 years received his third living
donor kidney transplant. His 2 prior renal allografts
had been diagnosed with recurrent FSGS, but their
failures were slowly progressive.
The first transplant was a living donor transplant
from his mother. Early complications included 2
biopsy-proven acute cellular rejection episodes that
were successfully treated, and 2 thrombotic events.
These consisted of renal vein thrombosis, requiring
thrombectomy, and lower extremity deep vein throm-
bosis. Because of these 2 events, lifelong anti-
coagulation was commenced. Eight months after the
first kidney transplantation, the patient had increasing
serum creatinine and proteinuria. A biopsy sample
showed FPE and swollen visceral epithelial cells. Pro-
teinuria progressed, and at 2 years post-transplantation
the biopsy sample showed established FSGS lesions
with diffuse FPE. Graft function continued to decline
slowly, with ongoing heavy proteinuria. At 10 years
post-transplantation a biopsy sample continued to
show similar features but with worsening interstitial
fibrosis and tubular atrophy. In preparation for a sec-
ond transplant, imaging revealed an allograft renal cell
carcinoma, and the patient underwent an allograft
nephrectomy 1 month prior to receiving his second
living donor transplant. At the time of the second
transplantation, the inferior vena cava (IVC) was noted
to be occluded by thrombus but with good collateral
drainage. The second transplant functioned well
initially. The protocol 3-month post-transplantation
allograft biopsy revealed moderate segmental podo-
cyte FPE that was interpreted as early recurrent FSGS
with low-level albuminuria (213617 mg/g). Conser-
vative therapy was undertaken. At 1 year, the albu-
minuria increased to 1386 mg/g and the protocol
biopsy showed 60% FPE. By 2 years, albuminuria
progressed to 3494 mg/g and the protocol biopsy
revealed 70% to 80% FPE with 1 of 12 glomeruli
exhibiting a segmental scar with foam cells and an
adhesion to the Bowman capsule. Based on these find-
ings, a course of PLEX was undertaken, but there was
no significant response. Rituximab was considered but
not administered, given the lack of response to the
PLEX. Albuminuria fluctuated between 2 and 4 g/g
creatinine over the remainder of the life of the allograft.
Eight years after this second transplantation, the pa-
tient underwent an allograft nephrectomy with simul-
taneous living donor transplant. This combined
procedure was undertaken because of the finding on
computed tomographic venography that the iliac veins
and IVC were occluded and that the venous pedicle of
the second allograft was the only feasible location to
attach the third kidney allograft.
For this third transplant, the patient underwent our
center’s current standard conditioning for high-risk
FSGS recipients. This consisted of 2 doses of
Figure 3. Trends of serum creatinine, random albumin/creatinine ratio, 24-hour albumin excretion, and serum albumin from case 3. IVC, inferior
vena cava.
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rituximab (1 g each) and 4 sessions of PLEX prior to
transplantation and careful follow-up of post-
transplantation albuminuria. The donor was a 68-
year-old man with treated hypertension.
The patient’s post-transplantation course was
complicated by slow graft function and fluctuating
proteinuria punctuated by repeated episodes of acute
kidney injury (Figure 3). On post-transplantation day
3, because of increasing albuminuria, PLEX was initi-
ated. A day 4 renal allograft biopsy showed acute
tubular injury and focal (20%30%) FPE. With sub-
sequent decline in albuminuria, PLEX was dis-
continued on day 5.
Graft function and albuminuria continued to fluc-
tuate, and a biopsy sample 50 days after transplantation
showed negligible FPE. At this time, because of the age
of the donor and the donor-derived chronic vascular
changes noted in the allograft, belatacept was
substituted for tacrolimus. Despite this, there was still
ongoing suboptimal renal function and fluctuating
albuminuria. Four months post-transplantation, biopsy
showed focal FPE with proteinuria of 2890 mg/24 h
(Figure 4).
At this 4-month visit, given the past medical history
of veno-occlusive disease and the atypical post-
transplantation course, other potential causes of sub-
optimal graft function and proteinuria were investi-
gated. Despite a normal renal allograft ultrasound and
Doppler not revealing renal vein thrombosis or
abnormal resistive indices, we proceeded with an
inferior venacavogram. A successful balloon veno-
plasty of the occluded vena cava was accomplished
(Figure 5). The pressure gradient from the external iliac
vein to the right atrium decreased from 11 to 12 mm Hg
to 5 to 6 mmHg. Following this, renal allograft function
improved dramatically, with normalization of urine
albumin excretion. Two months later, to avoid possible
restenosis, a repeat cavogram was performed with
stenting of the inferior vena cava (Figure 5).
At the 2-year protocol visit, the patient continued to
have normal urine albumin excretion. The protocol 2-
year post-transplantation biopsy sample showed
intact podocyte foot processes.
The collection of data and presentation of these cases
and this study was approved by the Mayo Clinic
Institutional Review Board (IRB# 18-007788) and are
Figure 4. Pathology of renal allograft biopsy samples from case 3. (a) Electron microscopy photomicrograph showing diffuse podocyte foot
process effacement and (b) light microscopy (original magnification 40, periodic acid–Schiff) demonstrating segmental sclerosis with hya-
linosis (both from the second renal allograft). (c) Electron microscopy photomicrograph demonstrating minimal podocyte foot process
effacement and (d) LM (original magnification 20, periodic acid–Schiff) showing normal glomeruli (both from the third renal allograft).
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consistent with the Principles of the Declaration of
Istanbul as outlined in the Declaration of Istanbul on
Organ Trafficking and Transplant Tourism.
DISCUSSION
These cases illustrate the difficulty, and possible pit-
falls, in making a diagnosis of recurrent FSGS. In the
first case, the pretransplantation probability of FSGS
was moderate. There was no native biopsy sample and
no clear history of nephrotic syndrome. The increasing
proteinuria and the light microscopic findings of 2 of
15 glomeruli with segmental lesions, and reactive
podocytes made the diagnosis of recurrent primary
idiopathic FSGS likely. This constellation of findings,
in many centers including our own, would have
resulted in initiation of PLEX with or without high-
dose corticosteroids to treat what would be bona fide
FSGS, be it recurrent or de novo. The rapid turnaround
of electron microscopy (EM) results that showed intact
podocyte foot processes allowed a pause and rethinking
of what this clinical scenario represented. Early
recurrent FSGS presents with diffuse FPE, generally
with normal glomerular histology on light micro-
scopy.S6,S7 This case had the opposite findings: namely,
FSGS lesions noted on LM, but intact foot processes on
EM in the setting of new-onset and worsening pro-
teinuria. The response to a short course of corticoste-
roids to treat the borderline cellular rejection was also
unlikely to have resulted in resolution of recurrent or
de novo FSGS.
So why did this patient develop this increasing
albuminuria? Why did it resolve with a short course of
corticosteroids? We postulate that the patient was do-
ing well until his 4-month visit, which included a
reassuring protocol biopsy. Subsequent to this, there
could have been a transient decrease in tacrolimus
levels resulting in the borderline cellular rejection that
was noted on the biopsy sample. The activation of the
immune system targeting the renal allograft with allo-
graft inflammation would have resulted in increased
inflammatory cytokines, including interferon-g and
tumor necrosis factor–a.S8 Tumor necrosis factor–a–
related pathways have been implicated in FSGS pre-
viously.S9–S12 With the homozygosity of the high-risk
APOL-1 alleles, the podocytes would have been sus-
ceptible to this inflammatory milieu,S13–S15 and some of
them succumbed, resulting in the increased proteinuria
and the segmental lesions that were seen on the biopsy
sample. The cell-mediated injury may not have been
diffuse in our case, given the patchy nature of cellular
rejection and as such may not have resulted in wide-
spread diffuse FPE. It may also have been very tran-
sient or improving prior to the biopsy, possibly due to
increased levels of the immunosuppressants, and was
not picked up at the time of the biopsy. In the mate
kidney that was placed in a highly sensitized patient
with increasing DSA, the more diffuse pattern of injury
commensurate with the humoral response may have
resulted in widespread podocyte dysfunction resulting
in the collapsing FSGS. A similar presentation was
previously reported in a transplant recipient.S16
APOL-1 has surfaced as a genetic variant that
partially explains the increased risk of hypertensive
ESRD associated with FSGS in the African American
population, as well as in other populations in West
Figure 5. Photographs from the cavogram of case 3 (a) occluded inferior vena cava (IVC) with guidewire traversing the obstruction, (b) after IVC
dilation, and (c) after IVC stenting.
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Africa or with West African heritage.S15,S17–S19 Patients
who are homozygous for 2 high-risk alleles either G1 or
G2 or a combination of both are at increased risk for
ESRD from FSGS and hypertension (odds ratio ¼ 10.5,
95% confidence interval ¼ 6.018.4, and odds ratio ¼
7.3, 95% confidence interval ¼ 5.69.5, respec-
tively).S17 These patients are also at increased risk for
HIV-associated nephropathy (HIVAN) with a lifetime
risk of ESRD of 50% versus 4%, respectively.S19,S20
APOL-1 is expressed in many tissues and is present in
the circulation.S21 That the constitutive APOL-1 in the
kidney is responsible for increased risk of dysfunction
was alluded to by the finding that kidneys from donors
who expressed 2 high-risk alleles had shorter graft
survival irrespective of the recipients’ APOL-1 sta-
tus.S14,S22 Our patient was homozygous for the average
risk (wild-type or reference) allele and the donor kidney
was homozygous for the high-risk allele (G 1), providing
further evidence that the intrinsic APOL-1, independent
of the circulating form, confers risk.S23,S24
In the third case, the converse regarding the pre-
and post-transplantation probability of FSGS was pre-
sent. The pretransplantation probability of recurrent
FSGS was very high, given a native kidney disease that
was diagnosed clinically and histologically and 2 prior
renal allografts with clinical and histological findings of
FSGS; hence the pretreatment with PLEX and ritux-
imab. The post-transplantation findings on biopsy were
less typical of what we frequently see. The FPE was
focal and not diffuse, the proteinuria fluctuated, and
renal function was erratic and suboptimal. One plau-
sible explanation that could be proposed for the lack of
diffuse FPE in this and similar situations is that this
was partially treated FSGS by the pretransplantation
PLEX and rituximab, post-transplantation PLEX, and
the standard triple immunosuppression therapy needed
for an allograft. The suboptimal renal allograft function
could also be attributed to an older and hypertensive
donor kidney showing minor vascular changes and
resulting in oversensitivity to tacrolimus. Noted,
however, was the lack of improvement with the tran-
sition to belatacept and discontinuation of the calci-
neurin inhibitor tacrolimus.S25–S27
The significant improvement in renal function and
albuminuria following venoplasty and subsequent
stenting of the inferior vena cava, with documented
improvement in the venous pressure gradient, is evi-
dence that the dysfunction was due to venous hyper-
tension. It is known that renal vein thrombosis
manifests with heavy proteinuria,S28 the mechanism
being an elevation in intraglomerular pressure and in-
crease in transcapillary filtration pressure gradient.
Partial occlusion or other causes of elevated venous
pressures such as right-sided heart failure can also lead
to similar findings.S29
Could this patient’s prior 2 allografts have been
affected by a similar phenomenon? In contrast to the
current allograft, the prior renal allografts had good
renal function for extended periods of time. Also, the
progression of proteinuria and the diffuse podocyte
FPE was more in keeping with recurrent FSGS. Could
this patient develop recurrent late FSGS? Time will tell.
This case does highlight the difficulty in investigating
venous hypertension as the cause of renal allograft
dysfunction. There is no reliable noninvasive means of
assessing renal vein pressures. We rely on renal allo-
graft ultrasound with Doppler to assess venous flow
and to exclude occlusion. Echocardiography can assess
right-sided heart pressures and in turn may reflect
elevated venous pressures, although only if a more
central origin is the cause. The only reliable means of
measuring renal vein pressure is via venography.
Venography is invasive and carries risks of the pro-
cedure as well as contrast exposure. Thus, there is
considerable hesitation in proceeding with such inva-
sive testing.
We demonstrated that even in the setting of biopsy
findings of FSGS and a post-transplantation state with
careful follow-up, there is difficulty in identifying
recurrent FSGS due to a circulating permeability fac-
tor. An incorrect labeling of a case has implications
for the individual patient being treated and for
studies attempting to identify the circulating perme-
ability factor. For the patient, this may result in un-
necessary therapy with associated comorbidity, cost,
and possible failure to identify a treatable condition.
For investigators, this will result in study groupings
that include heterogeneous cases, increasing the like-
lihood of identifying markers that are in common
pathways for proteinuric renal disease or podocyte
injury, and may not identify the circulating perme-
ability factor(s).
In conclusion, donor derived APOL-1 high-risk al-
leles intrinsic to the renal allograft, and not the recip-
ient, confer risk of proteinuria and development of
FSGS lesion in the kidney. These allografts may be
susceptible to the injurious effects of both the cellular
and humoral arms of the immune system. Venous hy-
pertension can mimic recurrent FSGS and, in the cor-
rect circumstance, warrants invasive testing. Scrutiny
of FSGS cohorts is imperative in the quest to identify
the circulating permeability factor(s).
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M
etformin is widely used as an antihyperglycemic
drug to treat patients with type 2 diabetes.
Because metformin is renally excreted and not metab-
olized, it can accumulate in patients with renal
insufficiency and cause lactic acidosis, known as
metformin-associated lactic acidosis (MALA).1,2 The re-
ported incidence of MALA ranges from 3 to 10 per
100,000 patient-years and is associated with a high
mortality rate. However, the full clinical context or
metformin blood concentration is often not reported,
making it challenging to distinguish metformin-
associated from metformin-induced lactic acidosis
(MILA), respectively.1
Normally, metformin shows 2-compartment phar-
macokinetics with a terminal half-life of 20 hours,
suggesting the existence of a deeper compartment.2
After oral administration to mice, accumulation of
metformin was observed in the gut, kidneys, and
liver.3 After 6 to 8 weeks of metformin therapy given
to drug-naive patients with type 2 diabetes, the
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